Literature DB >> 12640560

Structure and function of the factor VIII gene and protein.

Arthur R Thompson1.   

Abstract

Factor (F) VIII is a large gene located near the terminus of the long arm of the X chromosome. It contains 26 exons that code for a signal peptide and a 2332 amino acid polypeptide with three different types of domains, namely A1-A2-B-A3-C1-C2. The A domains are homologous with each other and those of ceruloplasmin; substitution into the known crystal structure of the copper binding protein produces molecular models. The large, central B domain is highly glycosylated but has a variable sequence, even among FVIIIs from different species. Most of B can be deleted and the resulting recombinant protein has essentially normal survival in circulation and corrects the bleeding tendency in hemophilia A patients. The C domains are similar to each other, and the crystal structure of a recombinant human C2 domain is known, allowing construction of a molecular model of C1. The FVIII protein is secreted as a heterodimer following at least two intracellular cleavages within the B domain. In circulation it is stabilized by binding to von Willebrand factor (vWF) with a plasma half-life of about 10 hours. After specific thrombin cleavages that remove the remainder of the B domain and one of the high-affinity von Willebrand factor binding sites, FVIII becomes heterotrimeric FVIIIa, capable of enhancing intrinsic FX activation by FIXa. Inactivation of FVIIIa occurs by A2 dissociation or by specific cleavages within A1 and A2 by activated protein C. Control of intrinsic FX activation is critical for hemostasis and thrombosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640560     DOI: 10.1055/s-2003-37935

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  20 in total

1.  Antihemophilic factor [recombinant], formulated with sucrose.

Authors: 
Journal:  P T       Date:  2010-09

2.  A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.

Authors:  Kevin R Viel; Deepa K Machiah; Diane M Warren; Manana Khachidze; Alfonso Buil; Karl Fernstrom; Juan C Souto; Juan M Peralta; Todd Smith; John Blangero; Sandra Porter; Stephen T Warren; Jordi Fontcuberta; Jose M Soria; W Dana Flanders; Laura Almasy; Tom E Howard
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

Review 3.  Clinical use of factor VIII and factor IX concentrates.

Authors:  Massimo Morfini; Antonio Coppola; Massimo Franchini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

4.  Influence of single nucleotide polymorphisms in factor VIII and von Willebrand factor genes on plasma factor VIII activity: the ARIC Study.

Authors:  Marco Campos; Ashley Buchanan; Fuli Yu; Maja Barbalic; Yang Xiao; Lloyd E Chambless; Kenneth K Wu; Aaron R Folsom; Eric Boerwinkle; Jing-fei Dong
Journal:  Blood       Date:  2012-01-04       Impact factor: 22.113

5.  Factor VIII haplotypes frequencies in Tunisian hemophiliacs A.

Authors:  Hejer Elmahmoudi; Nejla Belhedi; Asma Jlizi; Kaouther Zahra; Balkis Meddeb; Amel Ben Ammar Elgaaied; Emna Gouider
Journal:  Diagn Pathol       Date:  2011-06-17       Impact factor: 2.644

Review 6.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

7.  The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.

Authors:  Lingxia Chen; Fuxiang Zhu; Juan Li; Hui Lu; Haiyan Jiang; Rita Sarkar; Valder R Arruda; Jinhui Wang; Jennifer Zhao; Glenn F Pierce; Qiulan Ding; Xuefeng Wang; Hongli Wang; Steven W Pipe; Xiang-Qin Liu; Xiao Xiao; Rodney M Camire; Weidong Xiao
Journal:  Mol Ther       Date:  2007-07-24       Impact factor: 11.454

8.  Inhibitors of factor VIII in black patients with hemophilia.

Authors:  Kevin R Viel; Afshin Ameri; Thomas C Abshire; Rathi V Iyer; Raymond G Watts; Charles Lutcher; Cynthia Channell; Shelley A Cole; Karl M Fernstrom; Shelley Nakaya; Carol K Kasper; Arthur R Thompson; Laura Almasy; Tom E Howard
Journal:  N Engl J Med       Date:  2009-04-16       Impact factor: 91.245

9.  Engineering Factor Viii for Hemophilia Gene Therapy.

Authors:  Sean A Roberts; Biao Dong; Jenni A Firrman; Andrea R Moore; Nianli Sang; Weidong Xiao
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-21

10.  High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

Authors:  Glaivy Batsuli; Wei Deng; John F Healey; Ernest T Parker; W Hunter Baldwin; Courtney Cox; Brenda Nguyen; Joerg Kahle; Christoph Königs; Renhao Li; Pete Lollar; Shannon L Meeks
Journal:  Blood       Date:  2016-07-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.